Clinical Trials Logo

Filter by:
NCT ID: NCT03879174 Not yet recruiting - Clinical trials for Breast Cancer Female

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Pembro
Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) designed to directly block the interaction between PD-1 and its ligands and enable the T cell to remain active and co-ordinate an attack on tumor cells. We hypothesise that the Clinical Benefit Rate (CBR) and progression free survival (PFS) of metastatic breast cancer patients who have ESR1 mutation will improve following administration of a combination of pembrolizumab and tamoxifen.

NCT ID: NCT03826888 Recruiting - Clinical trials for Anti-Mullerian Hormone Isoforms

Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders

Start date: February 25, 2019
Phase:
Study type: Observational

This study wants to evaluate significant clinical impact of different AMH isoforms in serum can be present or absent in expected poor responder participants. The specific AMH isoforms could therefore be measured in expected poor responder participants in order to obtain a more realistic clinical picture and therefore be able to give proper information to the participants and selection of medication dose for ovarian stimulation.

NCT ID: NCT03823339 Enrolling by invitation - Clinical trials for Diabetes Mellitus, Type 2

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

INTENSIFY
Start date: January 29, 2019
Phase:
Study type: Observational

The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.

NCT ID: NCT03803462 Recruiting - Behçet Disease Clinical Trials

Behçet's Disease Overall Damage Index

BODI
Start date: August 1, 2017
Phase:
Study type: Observational

Damage in vasculitis, as well as in other chronic inflammatory disorders, accrues over time resulting in impairment of quality of life, development of disability and increased mortality. For these reasons, damage represents an important outcome to be assessed and measured both in trials and clinical practice. Currently, the most widely used assessment tool for damage in vasculitis is the Vasculitis Damage Index (VDI). However, VDI was developed for a no specific type of vasculitis and it appears to be more suitable for damage assessment in ANCA-associated vasculitis than in Behçet' disease (BD). BD is a chronic and multisystem inflammatory disorder classified among vasculitides. As well as in other vasculitides, disease activity and treatment in BD can result in the development and accumulation of irreversible organ damage, such as blindness, tissue loss and a wide range of neurologic disorders. Recently the OMERACT has defined the Core Set domain of Outcome Measures for BD. Despite damage is included in the OMERACT outcome core set for rheumatic disease, a specific assessment tool for BD is currently not available. The aim of this study is to develop and validate the first tool for describing and measuring organ damage in patients with Behçet Disease (Behçet's disease Overall Damage index - BODI).

NCT ID: NCT03740880 Recruiting - Clinical trials for the Number of Mature Oocytes

Trigger Time in Advanced Maternal Age Patients With Low AMH

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

The investigators want to verify if advanced maternal age patients with a low Anti-Müllerian hormone (AMH) level may benefit from an early trigger time (compared to a late trigger).

NCT ID: NCT03725969 Completed - Insulin Sensitivity Clinical Trials

Effect of Camel Milk on Insulin and Incretin Response

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

To examine the differential effect of camel and cow milk on the physiological response, to a liquid mixed-meal challenge, in people with normal glucose tolerance

NCT ID: NCT03724136 Recruiting - Alzheimer Disease Clinical Trials

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

ACIST
Start date: October 24, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and socialization issues which occur in adult Autism Spectrum Disorder. The use of Near Infrared Light, in conjunction with the use of BMSC, will also be assessed.

NCT ID: NCT03708991 Recruiting - Genetic Condition Clinical Trials

Effectiveness of PGT-A: IVF Versus ICSI

Start date: November 8, 2018
Phase:
Study type: Observational [Patient Registry]

The investigators want to investigate if the use of conventional in vitro fertilization (IVF) can generate more euploid embryos as compared to intracytoplasmic sperm injection (ICSI). To verify this, the investigators will inject half of the oocytes by ICSI and the other half of the oocytes will be inseminated by conventional IVF. The most important aim is to see if IVF is able to generate more euploid embryos.

NCT ID: NCT03703869 Active, not recruiting - Diabetes Clinical Trials

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.

ATOS
Start date: March 6, 2018
Phase:
Study type: Observational

Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c). Secondary Objectives: - Assess effectiveness in achieving glycemic goal measured by HbA1c; - Assess effectiveness on change in HbA1c, fasting plasma glucose (FPG) and self-monitored plasma glucose (SMPG) ; - Assess requirement for intensification of therapy by additional antidiabetics. - Assess incidence of hypoglycemia; - Assess other safety endpoints: adverse events (AEs), serious adverse events (SAEs); - Assess change in body weight.

NCT ID: NCT03686059 Recruiting - Clinical trials for Ocular Surface Disease

Outcome of Punctal Plugs on Ocular Surface Disease

Start date: July 2, 2018
Phase: Phase 4
Study type: Interventional

Ocular surface disease is a common adverse effect of systemic isotretinoin therapy. The investigators consider that punctal plugs is simple procedure with good patient compliance for treatment of ocular surface disease associated with systemic isotretinoin therapy